Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,758 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acquired Immune Deficiency Syndrome Clear all
Completed Not applicable Interventional Accepts healthy volunteers

ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs

NCT05270135
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Hiv, Hepatitis C, Bloodstream Infection
Interventions
ASAP
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 17, 2026, 4:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

PrEP Intervention in Prince George's County, Maryland

NCT06141408
View directory record Official record
Conditions
Hiv, Mental Health Issue, Support, Family
Interventions
MPowerment PrEP Promotion Intervention
Behavioral
Lead sponsor
George Mason University
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 4 Interventional Results available

Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV

NCT00527618
View directory record Official record
Conditions
Genital Herpes, HIV Infection
Interventions
valacyclovir, acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Sep 17, 2026, 4:40 AM EDT
Withdrawn Phase 4 Interventional

Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

NCT02990312
View directory record Official record
Conditions
Hiv, Kidney Transplant, HIV Reservoir, CCR5
Interventions
Sirolimus + Maraviroc
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 17, 2026, 4:40 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Clinic-Community Bridge to Improve Health Outcomes for Abused Women Living With HIV/AIDS

NCT07553312
View directory record Official record
Conditions
Adult Women Living With HIV/AIDS, Intimate Partner Violence
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine

NCT00000628
View directory record Official record
Conditions
HIV Infections
Interventions
L-697,661, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 17, 2026, 4:40 AM EDT
Completed No phase listed Observational

A Pilot Study of Adherence to Oral Medication and Health Beliefs of Adolescents With HIV and Their Mothers

NCT00001699
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 4:40 AM EDT
Enrolling by invitation Not applicable Interventional

Evaluating an Algorithm-Based Implementation Strategy to Improve HIV Care Outcomes

NCT07279376
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
predictive emergency room alerts (pERA), Standard of care
Other
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older
Enrollment
2,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 2 Interventional

Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

NCT00000838
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 2 Interventional

A Study of Azidothymidine in HIV-Infected Children

NCT00000982
View directory record Official record
Conditions
Encephalopathies, HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 2 Interventional

Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC

NCT00001040
View directory record Official record
Conditions
HIV Infections
Interventions
Saquinavir, Zidovudine, Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Birmingham, Alabama • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

NCT01734850
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
Drug · Biological
Lead sponsor
Calimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

NCT05896748
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions
Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Macon, Georgia • Austin, Texas • Bellaire, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

NCT03823911
View directory record Official record
Conditions
Cardiovascular Diseases, Hepatitis C, Hiv
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

NCT06012136
View directory record Official record
Conditions
HIV Infections
Interventions
VH4004280, Placebo, VH4011499
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 17, 2026, 4:40 AM EDT
Recruiting Not applicable Interventional

Enhancing the Organizational Social Context to Improve Viral Suppression and Retention in HIV Care

NCT06462807
View directory record Official record
Conditions
HIV/AIDS
Interventions
ARC
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00058734
View directory record Official record
Conditions
HIV Infections
Interventions
Dendritic Cells Pulsed with HIV antigens
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2007 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 1 Interventional

A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC

NCT00000753
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

NCT00002379
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Levocarnitine, Adefovir dipivoxil, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Phase 2 Interventional

CMV Retinitis Retreatment Trial

NCT00000766
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Not applicable Interventional Results available

CPT-L to Improve Outcomes for Individuals With HIV and PTSD

NCT05275842
View directory record Official record
Conditions
PTSD, Hiv
Interventions
Cognitive Processing Therapy- Lifesteps (CPT-L), Lifesteps
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 17, 2026, 4:40 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women

NCT02431273
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Prophylaxis
Interventions
TDF IVR, TDF-FTC IVR, TDF-FTC-MVC IVR
Drug
Lead sponsor
Auritec Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 17, 2026, 4:40 AM EDT